Dyadic International will announce Q2 2025 financial results and host a conference call on November 12, 2025.
Quiver AI Summary
Dyadic International, Inc. has announced that it will release its financial results for the second quarter of 2025 and hold a corporate update conference call on November 12, 2025, at 5:00 p.m. Eastern Time. Interested parties can join the call using provided dial-in numbers, and a webcast will be available for those who prefer online access. An archived version of the webcast will be accessible on the company's website shortly after the live event. Dyadic is a biotechnology company that specializes in producing precision engineered functional proteins for various industries, utilizing its proprietary gene expression platforms. The release also includes forward-looking statements regarding the company's future performance and cautions investors to consider potential risks as detailed in their SEC filings.
Potential Positives
- Dyadic has scheduled a corporate update conference call for November 12, 2025, providing an opportunity for stakeholders to engage directly with management.
- The company will report its financial results for the second quarter 2025, indicating transparency and accountability in its financial performance.
- Dyadic's proprietary microbial platforms and gene expression technologies are highlighted, showcasing its innovative capabilities in biotechnology and potential for growth in various markets.
- The availability of a replay of the webcast within 24 hours enhances accessibility for stakeholders who cannot attend the live event.
Potential Negatives
- The mention of significant forward-looking statements accompanied by a cautionary note about the potential for actual events to differ materially may raise concerns among investors about the reliability of the company's future projections.
- The need for ongoing updates and disclosures regarding risks and uncertainties could indicate potential challenges in the company’s business strategy and execution.
- The focus on upcoming financial results could suggest that previous quarters may not have met expectations, prompting the need for a corporate update to address investor concerns.
FAQ
When will Dyadic report its second quarter financial results?
Dyadic will report its second quarter financial results on Wednesday, November 12, 2025.
How can I join Dyadic's corporate update conference call?
You can join by dialing +1-877-407-0784 for toll-free access or +1-201-689-8560 for international calls.
What time is the Dyadic conference call scheduled?
The conference call is scheduled for 5:00 p.m. Eastern Time on Wednesday, November 12, 2025.
Where can I access the webcast of the conference call?
The webcast can be accessed at https://viavid.webcasts.com/starthere.jsp?ei=1706029&tp_key=b177e95e36.
Who can I contact for questions before the conference call?
You can email your questions to [email protected] before the conference call.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$DYAI Insider Trading Activity
$DYAI insiders have traded $DYAI stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $DYAI stock by insiders over the last 6 months:
- JOSEPH P HAZELTON (President and COO) purchased 26,000 shares for an estimated $24,700
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$DYAI Hedge Fund Activity
We have seen 14 institutional investors add shares of $DYAI stock to their portfolio, and 8 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BANDERA PARTNERS LLC removed 183,600 shares (-11.7%) from their portfolio in Q2 2025, for an estimated $181,764
- ALPHACORE CAPITAL LLC added 50,759 shares (+inf%) to their portfolio in Q2 2025, for an estimated $50,251
- CHAPIN DAVIS, INC. added 49,155 shares (+5.6%) to their portfolio in Q3 2025, for an estimated $58,002
- VANGUARD GROUP INC added 46,318 shares (+5.7%) to their portfolio in Q2 2025, for an estimated $45,854
- RENAISSANCE TECHNOLOGIES LLC added 16,629 shares (+53.7%) to their portfolio in Q2 2025, for an estimated $16,462
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC removed 16,336 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $16,172
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 14,692 shares (-17.6%) from their portfolio in Q2 2025, for an estimated $14,545
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$DYAI Analyst Ratings
Wall Street analysts have issued reports on $DYAI in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 10/23/2025
To track analyst ratings and price targets for $DYAI, check out Quiver Quantitative's $DYAI forecast page.
Full Release
JUPITER, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it will report its financial results for the second quarter 2025 and host a corporate update conference call on Wednesday, November 12, 2025.
Conference Call Information
Date: Wednesday, November 12, 2025
Time : 5:00 p.m. Eastern Time
Dial-in numbers: Toll Free: +1-877-407-0784; International +1-201-689-8560
Conference ID: 13751389
Webcast Link:. https://viavid.webcasts.com/starthere.jsp?ei=1706029&tp_key=b177e95e36 . An archive of the webcast will be available within 24 hours after completion of the live event and will be accessible on the Investor Relations section of the Company's website at www.dyadic.com . To access the replay of the webcast, please follow the webcast link above.
If you have any questions that you would like to ask management during the Q&A session, please email [email protected] prior to the conference call.
About Dyadic Applied BioSolutions
Dyadic Applied BioSolutions is a global biotechnology company that uses its proprietary microbial platforms to produce recombinant proteins that are sold or licensed to partners across the life sciences, food and nutrition, and bio-industrial markets. These high-quality proteins are designed to enable customers to develop more efficient, scalable, and sustainable products. Dyadic’s C1 and Dapibus™ expression systems support flexible, cost-effective manufacturing, and are the foundation of a growing portfolio of commercial and partnered programs. For more information, please visit www.dyadic.com .
Safe Harbor Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding Dyadic International’s expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, such as the success of our clinical trial and interest in our protein production platforms, our research projects and third-party collaborations, as well as the availability of necessary funding. Actual events or results may differ materially from those in the forward-looking statements because of various important factors, including those described in the Company’s most recent filings with the SEC. Dyadic assumes no obligation to update publicly any such forward-looking statements, whether because of new information, future events or otherwise. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled “Risk Factors” in Dyadic’s annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic’s periodic filings with the SEC, which are accessible on the SEC’s website and at www.dyadic.com .
Contact:
Dyadic Applied BioSolutions
Ping Rawson
Chief Financial Officer
Phone: (561) 743-8333
Email:
[email protected]
